Determinants of Metabolic Syndrome Among Patients Receiving Anti-Retro-Viral Treatment in A Tertiary Hospital, Central Ethiopia: Unmatched Case–Control Study
Godana Jarso,Haji Aman,Abebe Megerso
DOI: https://doi.org/10.2147/tcrm.s453699
2024-03-18
Therapeutics and Clinical Risk Management
Abstract:Godana Jarso, 1 Haji Aman, 2 Abebe Megerso 2 1 Department of Internal Medicine, Adama Hospital Medical College, Adama, Oromia, Ethiopia; 2 Department of Public Health, Adama Hospital Medical College, Adama, Oromia, Ethiopia Correspondence: Abebe Megerso Adlo, Tel +251911044525, Email ; Purpose: Scaling up antiretroviral treatment (ART) reduces morbidity and mortality among people living with HIV/AIDS (PLHA). This success is challenged by the constellation of interrelated metabolic disorders such as metabolic syndrome (MetS). Given the changing ART regimens and schedules, increasing patient age and methodological limitations, existing evidence regarding the determinants of MetS remains inconclusive. Therefore, in the current study, we aimed to identify the determinants of MetS in patients receiving ART at a tertiary hospital in central Ethiopia. Patient and Methods: We conducted an unmatched case–control study that included 393 patients with a case-to-control ratio of 1 to 2. Data were collected by interviewing patients, reviewing charts, physical examinations, and laboratory testing. The data were entered into Epi-Info version 7.2 and analyzed using SPSS version 26. A binary logistic regression analysis was used to identify the determinants of MetS. The adjusted odds ratio (AOR) with a 95% confidence interval (CI) was used to estimate the strength of the association between MetS and its determinants. Statistical significance was set at p-value < 0.05. Results: In this study, higher odds of developing MetS were identified among patients aged 40– 60 years (AOR 3.75; 95% CI: 1.66– 8.49) and those older than 60 years (AOR 6.18; 95% CI: 2.12– 17.95) than among those aged < 40 years. Similarly, higher odds were observed among patients who frequently consumed animal source foods than among those who consumed cereals or vegetables (AOR, 1.94; 95% CI, 1.03– 3.63), those who had HIV lipodystrophy (AOR 1.73; 95% CI: 1.05– 2.86), those who were treated with stavudine (AOR 3.08; 95% CI: 1.89– 5.04), and those who were treated with zidovudine (AOR 1.71, 95% CI: 1.02– 2.88) compared to their counterparts. Conclusion: Older age, diet from animal sources, exposure to zidovudine or stavudine, and the presence of lipodystrophy were independent determinants of MetS. Keywords: adama, cardiometabolic, diabetes, dyslipidemia, hypertension, obesity Metabolic syndrome (MetS) is a constellation of interrelated metabolic conditions including abdominal obesity, elevated blood pressure, dyslipidemia, and hyperglycemia. 1 Several criteria were used to define MetS by different organizations. MetS was defined by the presence of insulin resistance (IR) or its markers, impaired glucose tolerance (IGT), or type-2 diabetes mellitus (T2DM), as essential components of the syndrome, along with at least two of the following parameters: elevated blood pressure, hypertriglyceridemia, and/or low high-density lipoprotein-cholesterol (HDL-c), central obesity, and microalbuminuria, with different weights given to each component. 2,3 In 2001, the National Cholesterol Education Program Adult Treatment Panel III (NCEP: ATPIII) published a new set of criteria, which included waist circumference, blood lipids, blood pressure (BP), and fasting glucose. These criteria differed from both the WHO and the European Group for the Study of Insulin Resistance (EGIR) definitions in that IR was not considered a mandatory component. 4 Subsequently, the International Diabetes Federation (IDF) published newer criteria with obesity as a prerequisite for the diagnosis of MetS, in an attempt to improve comparability in different settings and better prediction of cardiovascular risk. 5 In 2009, the joint interim statement (JIS) of the IDF Task Force on Epidemiology and Prevention, the National Heart, Lung, and Blood Institute, the American Heart Association, the World Heart Federation, the International Atherosclerosis Society, and the International Association for the Study of Obesity suggested using the IDF global consensus definition as the presence of three or more of the five parameters but without central obesity as an obligatory parameter. 6 A major importance of MetS is that it is an important predictor of cardiovascular disease (CVD) and T2DM risks. 7 Studies have shown that adult individuals with MetS have three times the risk and a five-fold greater risk of acquiring CVDs and T2DM, respectively. 8 The introduction and expansion of antiretroviral therapy (ART) in the mid-1990s has led to a decline in morbidity and mortality among PLHA, but was later followed by an increase in cardiometabolic diseases such as obesity, hypertension, dyslipidemia, and T2DM.< -Abstract Truncated-
health care sciences & services